HEALTH-RELATED QUALITY-OF-LIFE OUTCOMES 4-YEARS AFTER TREATMENT WITH VALOCTOCOGENE ROXAPARVOVEC
FP Caretaa, B Madanb, MC Ozeloc, G Kenetd, S Choue, S Pipef, A Leavittg, A Ruizh, E Dashiell-Ajei, J Mahlanguj
a Universidade Federal do Espírito Santo (UFES), Vitória, ES, Brazil
b Guy's and St Thomas'NHS Foundation Trust, London, UK
c Centro de Hematologia e Hemoterapia (Hemocentro), Department of Internal Medicine, Faculdade de Ciências Médicas (FCM), Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
d The National Hemophilia Center and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Tel Aviv University
e Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
f Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA
g Adult Hemophilia Treatment Center, University of California San Francisco, San Francisco, CA, USA
h National Bleeding Disorders Foundation, Oakland Park, FL, USA
i BioMarin Pharmaceutical Inc., Novato, CA, USA
j Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and NHLS, Johannesburg, South Africa
Ver másLido
485
Vezesque se leu este artigo
177
Total PDF
308
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 7 | 7 | 4 | 11 |
| 2025 6 | 55 | 19 | 74 |
| 2025 5 | 45 | 7 | 52 |
| 2025 4 | 34 | 8 | 42 |
| 2025 3 | 41 | 19 | 60 |
| 2025 2 | 32 | 15 | 47 |
| 2025 1 | 21 | 22 | 43 |
| 2024 12 | 21 | 24 | 45 |
| 2024 11 | 37 | 37 | 74 |
| 2024 10 | 15 | 22 | 37 |
